Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:50:27.130Z.
Calculation as of: 2026-10-06T15:50:27.130Z.
Quote observation: 2026-10-06T15:49:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$816.88M
Price/OCF Ratio
N/A
TTM Avg
185.06
3Y Avg
185.06
5Y Avg
185.06
Market Cap
$799.38M
Price/OCF Ratio
N/A
TTM Avg
422.02
3Y Avg
258.29
5Y Avg
228.94
Market Cap
$786.94M
Price/OCF Ratio
N/A
TTM Avg
2.47
3Y Avg
2.47
5Y Avg
6.38
Market Cap
$774.83M
Price/OCF Ratio
13.92
TTM Avg
12.12
3Y Avg
13.02
5Y Avg
20.17
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $804.23M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $803.93M | 9.08 | 9.81 | 9.87 | 15.02 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $816.88M | N/A | 185.06 | 185.06 | 185.06 |
| AdaptHealth Corp. (AHCO)vs › | $796.23M | 1.37 | 2.23 | 2.49 | 4.68 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $799.38M | N/A | 422.02 | 258.29 | 228.94 |
| Ardelyx, Inc. (ARDX)vs › | $816.21M | N/A | 5.49 | 6.61 | 6.61 |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 59.38 | 59.38 | 59.38 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $786.94M | N/A | 2.47 | 2.47 | 6.38 |
| Mesa Laboratories, Inc. (MLAB)vs › | $774.83M | 13.92 | 12.12 | 13.02 | 20.17 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $776.26M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
